title: Correlation between CD29 density on CD8+ lymphocytes and serum IgG in systemic lupus erythematosus.
abstract: The purpose of this paper is to establish whether there is increased lymphocyte adhesion molecule density in systemic lupus erythematosus (SLE), which could alter the migration pathways and activation thresholds of lymphocytes and thus contribute to the pathogenesis of the disease. We analysed the CD11a, CD29 and CD2 bound antibody molecule (bam) density on the CD4+ and CD8+ CAMhigh (primed) lymphocytes of 28 SLE patients (8 active and 20 inactive by BILAG), using reproducible flow cytometric measurements, standardized with fluorescent beads and antibodies of known fluorescein: protein ratios. In a second patient cohort (17 patients), we investigated whether CD29 density on CD8+ cells correlated with measures of humoral (serum IgG) or cellular (urine neopterin) activation. In the first cohort, 36% of patients had elevated CD29 (beta 1 integrin) density on CD8+ cells. In the second cohort, CD29 density on CD8+ cells was found to be closely associated with total plasma IgG (r = 0.71, P = 0.001), but not with urine neopterin, disease activity (BILAG) or drug treatment. We conclude that CD29 on CD8+ cells is associated with B cell activation in SLE.
authors.affiliation: Department of Immunology, University Hospital, Nottingham, UK.
authors.forename: M
authors.initials: M
authors.lastname: Pallis
authors.forename: K L
authors.initials: KL
authors.lastname: Lim
authors.forename: J M
authors.initials: JM
authors.lastname: Gardner-Medwin
authors.forename: R A
authors.initials: RA
authors.lastname: Robins
authors.forename: R J
authors.initials: RJ
authors.lastname: Powell
mesh_terms: D015703:Antigens, CD / Q000032:analysis*; D001379:Azathioprine / Q000627:therapeutic use; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D015331:Cohort Studies; D004311:Double-Blind Method; D019085:Fluorescent Antibody Technique, Direct; D006801:Humans; D007154:Immune System Diseases / Q000097:blood / Q000276:immunology*; D007074:Immunoglobulin G / Q000097:blood*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D019012:Integrin beta1 / Q000032:analysis*; D008137:Longitudinal Studies; D008180:Lupus Erythematosus, Systemic / Q000097:blood / Q000188:drug therapy / Q000276:immunology*; D008213:Lymphocyte Activation; D012044:Regression Analysis; D013997:Time Factors
chemical_list: D015703:Antigens, CD; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D019012:Integrin beta1; D001379:Azathioprine